Alpha-1 adrenergic receptor (ADRA1)

Alpha-1 adrenergic receptors are G protein-coupled receptors located on the smooth muscle cells of blood vessels within the nasal mucosa (StatPearls: Physiology, Adrenergic Receptors). Their primary biological role in this tissue is to mediate vasoconstriction in response to sympathetic nervous system activity or exogenous agonists. In clinical conditions such as allergic rhinitis or the common cold, these blood vessels become dilated and permeable, leading to tissue swelling and the physical obstruction of the nasal passages. Pharmacological targeting of these receptors with decongestant drugs like phenylephrine or oxymetazoline induces rapid vasoconstriction, which effectively reduces mucosal edema and restores airflow (NCBI: Nasal Decongestants). While highly effective for acute relief, prolonged use of topical agonists can lead to receptor down-regulation and a paradoxical increase in congestion upon drug withdrawal, known as rhinitis medicamentosa. Furthermore, because alpha-1 receptors are widely distributed in the systemic vasculature, these drugs must be used with caution in patients with cardiovascular disease due to the risk of elevated blood pressure and heart rate (PubChem: Phenylephrine).

Other names

Alpha-1 adrenoceptorα1-adrenoceptorAlpha-1 adrenoreceptorADRA1AADRA1BADRA1D

Agonism of alpha-1 adrenergic receptors on the smooth muscle of nasal mucosal blood vessels activates the Gq protein-coupled signaling pathway. This leads to the activation of phospholipase C, which generates inositol trisphosphate (IP3) and diacylglycerol (DAG), resulting in an increase in intracellular calcium levels (StatPearls: Physiology, Adrenergic Receptors). The elevated calcium triggers smooth muscle contraction, causing vasoconstriction of the dilated nasal blood vessels. This reduction in vessel diameter and blood volume decreases mucosal edema and shrinks the swollen nasal membranes, thereby reducing nasal airway resistance and relieving congestion (NCBI: Nasal Decongestants).